CL2020000601A1 - Composición farmacéutica. - Google Patents
Composición farmacéutica.Info
- Publication number
- CL2020000601A1 CL2020000601A1 CL2020000601A CL2020000601A CL2020000601A1 CL 2020000601 A1 CL2020000601 A1 CL 2020000601A1 CL 2020000601 A CL2020000601 A CL 2020000601A CL 2020000601 A CL2020000601 A CL 2020000601A CL 2020000601 A1 CL2020000601 A1 CL 2020000601A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- fxr
- oral administration
- pharnesoid
- trifluorometoxi
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA PARA LA ADMINISTRACIÓN ORAL QUE COMPRENDE UN AGONISTA DEL RECEPTOR FARNESOIDE X (FXR) NO BILIAR, ÁCIDO 2–[(1R,3R,5S)–3–({5–CICLOPROPILO–3–[2–(TRIFLUOROMETOXI)FENIL]–1,2–OXAZOL–4–IL}METOXI)–8–AZABICICLO[3.2.1]OCTAN–8–IL]–4–FLUORO–1,3–BENZOTIAZOL–6–CARBOXÍLICO, O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, Y POR LO MENOS UN EXCIPIENTE LÍPIDO; A UNA CÁPSULA PARA LA ADMINISTRACIÓN ORAL QUE COMPRENDE DICHA COMPOSICIÓN FARMACÉUTICA; AL USO DE DICHA COMPOSICIÓN FARMACÉUTICA PARA EL TRATAMIENTO DE UNA AFECCIÓN O UN TRASTORNO MEDIADO POR FXR; Y A UN PROCESO PARA LA PREPARACIÓN DE DICHA COMPOSICIÓN FARMACÉUTICA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762557298P | 2017-09-12 | 2017-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000601A1 true CL2020000601A1 (es) | 2020-09-11 |
Family
ID=63686041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000601A CL2020000601A1 (es) | 2017-09-12 | 2020-03-10 | Composición farmacéutica. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11207313B2 (es) |
| EP (1) | EP3681485A1 (es) |
| JP (1) | JP2020533297A (es) |
| KR (1) | KR20200052280A (es) |
| CN (1) | CN111093637A (es) |
| AR (1) | AR114930A1 (es) |
| AU (1) | AU2018332191B2 (es) |
| BR (1) | BR112020004663A2 (es) |
| CA (1) | CA3072559A1 (es) |
| CL (1) | CL2020000601A1 (es) |
| IL (1) | IL272419A (es) |
| MX (1) | MX2020002432A (es) |
| RU (1) | RU2020111980A (es) |
| TW (1) | TW201919626A (es) |
| WO (1) | WO2019053581A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114728955A (zh) * | 2019-11-29 | 2022-07-08 | 广东东阳光药业有限公司 | Tropifexor的新晶型及其制备方法 |
| CN114728954B (zh) * | 2019-11-29 | 2023-10-17 | 广东东阳光药业股份有限公司 | Tropifexor的新晶型及其制备方法 |
| WO2021233461A1 (zh) * | 2020-05-22 | 2021-11-25 | 苏州晶云药物科技股份有限公司 | 苯并噻唑类化合物的新晶型及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252670A1 (en) | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
| US20070265340A1 (en) * | 2006-01-05 | 2007-11-15 | Shalwitz Robert A | Treatment of fatty liver |
| CA2779736A1 (en) * | 2009-11-03 | 2011-05-12 | Bernard Charles Sherman | Stable pharmaceutical formulations comprising lubiprostone |
| JO3337B1 (ar) * | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| ES2902404T3 (es) | 2016-02-22 | 2022-03-28 | Novartis Ag | Métodos para utilizar agonistas de fxr. |
| US11110083B2 (en) | 2016-02-22 | 2021-09-07 | Novartis Ag | Methods for treating liver disorders using FXR agonists |
| LT3419625T (lt) | 2016-02-22 | 2021-07-26 | Novartis Ag | Fxr agonistų panaudojimo būdai |
| WO2018039384A1 (en) | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators |
| ES2927019T3 (es) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
-
2018
- 2018-09-07 AR ARP180102544A patent/AR114930A1/es unknown
- 2018-09-10 US US16/125,809 patent/US11207313B2/en active Active
- 2018-09-10 TW TW107131663A patent/TW201919626A/zh unknown
- 2018-09-11 RU RU2020111980A patent/RU2020111980A/ru unknown
- 2018-09-11 MX MX2020002432A patent/MX2020002432A/es unknown
- 2018-09-11 BR BR112020004663-9A patent/BR112020004663A2/pt not_active Application Discontinuation
- 2018-09-11 WO PCT/IB2018/056904 patent/WO2019053581A1/en unknown
- 2018-09-11 EP EP18779051.4A patent/EP3681485A1/en not_active Withdrawn
- 2018-09-11 AU AU2018332191A patent/AU2018332191B2/en not_active Ceased
- 2018-09-11 CN CN201880057264.7A patent/CN111093637A/zh active Pending
- 2018-09-11 CA CA3072559A patent/CA3072559A1/en active Pending
- 2018-09-11 JP JP2020513606A patent/JP2020533297A/ja active Pending
- 2018-09-11 KR KR1020207006661A patent/KR20200052280A/ko not_active Application Discontinuation
-
2020
- 2020-02-02 IL IL272419A patent/IL272419A/en unknown
- 2020-03-10 CL CL2020000601A patent/CL2020000601A1/es unknown
-
2021
- 2021-11-17 US US17/529,078 patent/US20220071983A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019053581A1 (en) | 2019-03-21 |
| TW201919626A (zh) | 2019-06-01 |
| CA3072559A1 (en) | 2019-03-21 |
| US20220071983A1 (en) | 2022-03-10 |
| IL272419A (en) | 2020-03-31 |
| AU2018332191A1 (en) | 2020-02-20 |
| JP2020533297A (ja) | 2020-11-19 |
| EP3681485A1 (en) | 2020-07-22 |
| AU2018332191B2 (en) | 2021-05-20 |
| AR114930A1 (es) | 2020-11-11 |
| CN111093637A (zh) | 2020-05-01 |
| RU2020111980A (ru) | 2021-10-13 |
| KR20200052280A (ko) | 2020-05-14 |
| US11207313B2 (en) | 2021-12-28 |
| BR112020004663A2 (pt) | 2020-09-15 |
| MX2020002432A (es) | 2020-07-13 |
| US20190076418A1 (en) | 2019-03-14 |
| RU2020111980A3 (es) | 2021-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000601A1 (es) | Composición farmacéutica. | |
| CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| EA201790525A1 (ru) | Применение агента, активирующего рецептор гамк, для получения седативного и анестезирующего лекарственного средства | |
| DOP2016000156A (es) | Composiciones farmacã¿uticas que comprenden azd9291. | |
| BR112012020271A2 (pt) | Benzisoxazóis e azabenzisoxazóis como potencializadores alostéricos de mglur4 composições e métodos de tratamentos de disfunção neurológica | |
| BR112016010383A2 (pt) | compostos de pyy seletivos e usos dos mesmos | |
| CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
| BR112017012396A2 (pt) | combinação farmacêutica que compreende um agonista seletivo do receptor s1p1 | |
| UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| BR112019021868A2 (pt) | Sal de um composto derivado de aminopiridina, forma cristalina do mesmo, e processo para a preparação do mesmo | |
| BR112018007947A2 (pt) | uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash | |
| BR112017026272A2 (pt) | ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto? | |
| PE20181296A1 (es) | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamiento de la enfermedad de parkinson | |
| CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| UY36123A (es) | Derivados de carboxamida | |
| CY1123877T1 (el) | Μορφες στερεας καταστασης αλατων νιλοτινιμπης | |
| UY36124A (es) | Derivados de carboxamida | |
| BR112017004948A2 (pt) | formulação farmacêutica. | |
| EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
| BR112016008060A8 (pt) | composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo | |
| BR112016013974A2 (pt) | Composto, composição farmacêutica, uso da composição farmacêutica e uso do composto | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| PE20170926A1 (es) | Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson | |
| PE20190382A1 (es) | Derivados etinilo |